Navigation Links
Global Markets for Enzyme Inhibitors
Date:6/26/2012

NEW YORK, June 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Enzyme Inhibitors

http://www.reportlinker.com/p0919317/Global-Markets-for-Enzyme-Inhibitors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY AND INFORMATION SOURCES

BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on "Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.)," which was given an award of excellence.

TABLE OF CONTENTS 

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED REPORTS 3

BCC ON-LINE SERVICES 4

DISCLAIMER 4

CHAPTER TWO: SUMMARY 5

SUMMARY 5

SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS

MARKET, THROUGH 2016 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS

MARKET, 2009-2016 ($ MILLIONS) 7

CHAPTER THREE: OVERVIEW 8

DEFINITIONS 8

STRUCTURE OF ENZYMES 8

ACTIVATION ENERGY 8

SPECIFICITY 9

ENZYME SUBSTRATE INTERACTION 9

CONDITIONS OF ENZYME ACTION 9

CLASSIFICATION OF ENZYMES 10

OXIDOREDUCTASES 10

TRANSFERASES 11

HYDROLASES 11

Nucleases 12

Phosphatases 12

LYASES 12

ISOMERASES 12

LIGASES 13

REAL-LIFE APPLICATIONS OF ENZYMES 13

METABOLIC ENZYMES 14

DIGESTIVE ENZYMES 15

FOOD ENZYMES 16

NEED FOR ENZYMES IN HUMAN BODY 16

PROTEOLYTIC ENZYMES 17

LIPOLYTIC ENZYMES 17

AMYLOLYTIC ENZYMES 17

RENNIN ENZYMES 18

WHAT ARE ENZYME INHIBITORS 18

WHY ENZYME INHIBITION 18

USE OF ENZYME INHIBITORS 19

MECHANISM OF ENZYME INHIBITION 19

TYPES OF ENZYME INHIBITORS 20

MIXED INHIBITION 20

COMPETITIVE INHIBITION 20

CLASSIFICATION OF ENZYME INHIBITORS 21

TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 21

OXIDOREDUCTASE INHIBITORS 22

Aldose Reductase Inhibitors 22

Statins 22

History of Development of Statins 23

TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 23

5-Alpha-Reductase Inhibitors 23

Aromatase Inhibitors 23

COX-2 Inhibitors 24

HYDROLASE INHIBITORS 24

Neuraminidase Inhibitors 24

Protease Inhibitors 25

TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 25

Phosphodiesterase Type 5 (PDE5) Inhibitors 26

Phosphodiesterase Type 4 (PDE4) Inhibitors 26

Angiotensin-Converting Enzyme (ACE) Inhibitors 27

TABLE 4 DEVELOPMENT OF ACE INHIBITORS 27

Proton Pump Inhibitors 28

TRANSFERASE INHIBITORS 28

Protein Kinase Inhibitors 28

Reverse Transcriptase Inhibitors 29

CHAPTER FOUR: REGULATORY ASPECTS 30

TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008–

2011 30

TABLE 5 (CONTINUED) 31

TABLE 5 (CONTINUED) 32

TABLE 5 (CONTINUED) 33

TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 34

TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008–2011 35

TABLE 7 (CONTINUED) 36

TABLE 7 (CONTINUED) 37

CHAPTER FIVE: MARKET LEADERS AND THEIR PRODUCTS FOR

ENZYME INHIBITORS 38

TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON

PUMP INHIBITORS 38

TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE

INHIBITORS 38

TABLE 9 (CONTINUED) 39

TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE

INHIBITORS 39

TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 40

TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF

AROMATASE INHIBITORS 40

TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE

TRANSCRIPTASE INHIBITORS 41

TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5

INHIBITORS 42

TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF

NEURAMINIDASE INHIBITORS 42

TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE

INHIBITORS 42

TABLE 16 (CONTINUED) 43

CHAPTER SIX: NEW DEVELOPMENTS 44

TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 44

TABLE 17 (CONTINUED) 45

TABLE 18 CLINICAL TRIALS OF STATINS 45

TABLE 18 (CONTINUED) 46

TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 47

TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE

INHIBITORS 47

TABLE 20 (CONTINUED) 48

TABLE 20 (CONTINUED) 49

TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 49

TABLE 21 (CONTINUED) 50

TABLE 21 (CONTINUED) 51

TABLE 21 (CONTINUED) 52

TABLE 21 (CONTINUED) 53

TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 54

TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 54

TABLE 23 (CONTINUED) 55

TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 55

TABLE 24 (CONTINUED) 56

TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 56

TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 57

NEW DRUGS IN CLINICAL TRIALS 58

TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 58

CHAPTER SEVEN: GLOBAL MARKETS 59

MARKET ANALYSIS 59

TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH

2016 ($ MILLIONS) 60

FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016

($ MILLIONS) 61

PROTON PUMP INHIBITORS 61

Market Overview 62

Market Revenue 63

TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS,

THROUGH 2016 ($ MILLIONS) 64

FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS,

2009-2016 ($ MILLIONS) 64

PROTEASE INHIBITORS 64

Market Overview 65

Market Revenue 66

TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 67

FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-

2016 ($ MILLIONS) 67

REVERSE TRANSCRIPTASE INHIBITORS 67

Market Overview 68

Market Overview (Continued) 69

Market Revenue 70

TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 70

FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, 2009-2016 ($ MILLIONS) 71

KINASE INHIBITORS 71

Market Overview 72

Market Overview (Continued) 73

Market Revenue 74

TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 74

FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 75

STATINS 75

Market Overview 76

Market Revenue 77

TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($

MILLIONS) 78

FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 78

AROMATASE INHIBITORS 78

Market Overview 79

Market Revenue 80

TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 80

FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-

2016 ($ MILLIONS) 81

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 81

Market Overview 82

Market Revenue 83

TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH

2016 ($ MILLIONS) 83

FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($

MILLIONS) 84

NEURAMINIDASE INHIBITORS 84

Market Overview 85

Market Revenue 85

TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 86

FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS,

2009-2016 ($ MILLIONS) 86

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 86

Market Overview 87

Market Revenue 88

TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016

($ MILLIONS) 88

FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($

MILLIONS) 89

MARKET SHARES 89

TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY

REGION, 2010 (%) 89

FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY

REGION, 2010 (%) 90

TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 90

FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 91

TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET

SHARES BY REGION, 2010 (%) 91

FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET

SHARES BY REGION, 2010 (%) 92

TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 92

FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010

(%) 93

TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010

(%) 93

FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION,

2010 (%) 94

TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 94

FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION,

2010 (%) 95

TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 95

FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010

(%) 96

TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY

REGION, 2010 (%) 96

FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY

REGION, 2010 (%) 97

TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 97

FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 98

MARKET BY APPLICATIONS 98

TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY

THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH

2016 ($ MILLIONS) 99

FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY

THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016 ($

MILLIONS) 100

CARDIOVASCULAR (CV) DISEASE 100

Cardiovascular (CV) Disease (Continued) 101

TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 102

FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 103

GASTROINTESTINAL DISORDERS 103

TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 104

FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 105

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 105

Acquired Immunodeficiency … (Continued) 106

TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN

HIV/AIDS, THROUGH 2016 ($ MILLIONS) 107

FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN

HIV/AIDS, 2009-2016 ($ MILLIONS) 107

HEPATITIS 108

TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN

HEPATITIS, THROUGH 2016 ($ MILLIONS) 109

FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN

HEPATITIS, 2009-2016 ($ MILLIONS) 109

CANCER 110

Cancer (Continued) 111

TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS

CANCERS, THROUGH 2016 ($ MILLIONS) 112

FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN

VARIOUS CANCERS, 2009-2016 ($ MILLIONS) 113

ERECTILE DYSFUNCTION (ED) 113

TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 114

FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 115

OTHERS 115

TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER

SECTORS, THROUGH 2016 ($ MILLIONS) 116

FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER

SECTORS, 2009-2016 ($ MILLIONS) 117

GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY

APPLICATION 117

TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY

APPLICATION, 2010 (%) 118

FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES,

2010 (%) 118

CHAPTER EIGHT: MARKETS IN THE UNITED STATES 119

MARKET ANALYSIS 119

TABLE 56 U S MARKET FOR ENZYME INHIBITORS, THROUGH

2016 ($ MILLIONS) 120

FIGURE 29 U S MARKET FOR ENZYME INHIBITORS, 2009-2016 ($

MILLIONS) 121

PROTON PUMP INHIBITORS (PPI) 121

Market Overview 121

Market Overview (Continued) 122

Market Revenue 123

TABLE 57 U S MARKET FOR PROTON PUMP INHIBITORS,

THROUGH 2016 ($ MILLIONS) 123

FIGURE 30 U S MARKET FOR PROTON PUMP INHIBITORS, 2009-

2016 ($ MILLIONS) 124

PROTEASE INHIBITORS 124

Market Overview 125

Market Revenue 126

TABLE 58 U S MARKET FOR PROTEASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 126

FIGURE 31 U S MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($

MILLIONS) 127

REVERSE TRANSCRIPTASE INHIBITORS 127

Market Overview 127

Market Overview (Continued) 128

Market Revenue 129

TABLE 59 U S MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 129

FIGURE 32 U S MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, 2009-2016 ($ MILLIONS) 129

KINASE INHIBITORS 130

Market Overview 130

Market Overview (Continued) 131

Market Revenue 132

TABLE 60 U S MARKET FOR KINASE INHIBITORS, THROUGH 2016

($ MILLIONS) 132

FIGURE 33 U S MARKET FOR KINASE INHIBITORS, 2009-2016 ($

MILLIONS) 132

STATINS 133

Market Overview 133

Market Overview (Continued) 134

Market Revenue 135

TABLE 61 U S MARKET FOR STATINS, THROUGH 2016 ($

MILLIONS) 135

FIGURE 34 U S MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 136

AROMATASE INHIBITORS 136

Market Overview 137

Market Revenue 137

TABLE 62 U S MARKET FOR AROMATASE INHIBITORS, THROUGH

2016 ($ MILLIONS) 138

FIGURE 35 U S MARKET FOR AROMATASE INHIBITORS, 2009-2016

($ MILLIONS) 138

PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 138

Market Overview 139

Market Revenue 140

TABLE 63 U S MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($

MILLIONS) 140

FIGURE 36 U S MARKET FOR PDE5 INHIBITORS, 2009-2016 ($

MILLIONS) 140

NEURAMINIDASE INHIBITORS 141

Market Overview 141

Market Revenue 141

TABLE 64 U S MARKET FOR NEURAMINIDASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 142

FIGURE 37 U S MARKET FOR NEURAMINIDASE INHIBITORS, 2009-

2016 ($ MILLIONS) 142

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 142

Market Overview 143

Market Revenue 144

TABLE 65 U S MARKET FOR ACE INHIBITORS, THROUGH 2016 ($

MILLIONS) 145

FIGURE 38 U S MARKET FOR ACE INHIBITORS, 2009-2016 ($

MILLIONS) 145

MARKET SHARES OF INDUSTRY LEADERS IN THE UNITED

STATES 145

PROTON PUMP INHIBITORS 145

TABLE 66 U S MARKET SHARES OF PROTON PUMP INHIBITOR

MANUFACTURERS, 2010 (%) 146

FIGURE 39 U S MARKET SHARES OF PROTON PUMP INHIBITOR

MANUFACTURERS, 2010 (%) 146

PROTEASE INHIBITORS 147

TABLE 67 U S MARKET SHARES OF PROTEASE INHIBITOR

MANUFACTURERS, 2010 (%) 147

FIGURE 40 U S MARKET SHARES OF PROTEASE INHIBITORS

MANUFACTURERS, 2010 (%) 147

KINASE INHIBITORS 148

TABLE 68 U S MARKET SHARES OF KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 148

FIGURE 41 U S MARKET SHARES OF KINASE INHIBITORS

MANUFACTURERS, 2010 (%) 148

STATINS 149

TABLE 69 U S MARKET SHARES OF STATINS MANUFACTURERS,

2010 (%) 149

FIGURE 42 U S MARKET SHARES OF STATINS MANUFACTURERS,

2010 (%) 149

AROMATASE INHIBITORS 150

TABLE 70 U S MARKET SHARES OF AROMATASE INHIBITOR

MANUFACTURERS, 2010 (%) 150

FIGURE 43 U S MARKET SHARES OF AROMATASE INHIBITOR

MANUFACTURERS, 2010 (%) 150

REVERSE TRANSCRIPTASE INHIBITORS 151

TABLE 71 U S MARKET SHARES OF REVERSE TRANSCRIPTASE

INHIBITOR MANUFACTURERS, 2010 (%) 151

FIGURE 44 U S MARKET SHARES OF REVERSE TRANSCRIPTASE

INHIBITOR MANUFACTURERS, 2010 (%) 152

PDE5 INHIBITORS 152

TABLE 72 U S MARKET SHARES OF PDE5 INHIBITOR

MANUFACTURERS, 2010 (%) 152

FIGURE 45 U S MARKET SHARES OF PDE5 MANUFACTURERS,

2010 (%) 153

NEURAMINIDASE INHIBITORS 153

TABLE 73 U S MARKET SHARES OF NEURAMINIDASE INHIBITOR

MANUFACTURERS, 2010 (%) 153

FIGURE 46 U S MARKET SHARES OF NEURAMINIDASE

MANUFACTURERS, 2010 (%) 154

ACE INHIBITORS 154

TABLE 74 U S MARKET SHARES OF ACE INHIBITOR

MANUFACTURERS, 2010 (%) 154

FIGURE 47 U S MARKET SHARES OF ACE MANUFACTURERS, 2010

(%) 155

MARKET BY APPLICATIONS 155

TABLE 75 U S ENZYME INHIBITORS MARKET BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 156

FIGURE 48 U S MARKET INHIBITORS MARKET BY THERAPEUTIC

CATEGORIES/DISEASE SECTORS, 2009-2016 ($ MILLIONS) 156

CARDIOVASCULAR (CV) DISEASES 157

Cardiovascular (CV) Diseases (Continued) 158

TABLE 76 U S MARKET OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 159

FIGURE 49 U S MARKET OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 159

GASTROINTESTINAL DISORDERS 160

TABLE 77 U S MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 160

FIGURE 50 U S MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 161

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 161

TABLE 78 U S MARKET OF ENZYME INHIBITORS IN HIV/AIDS,

THROUGH 2016 ($ MILLIONS) 162

FIGURE 51 U S MARKET OF ENZYME INHIBITORS IN HIV/AIDS,

2009-2016 ($ MILLIONS) 163

HEPATITIS 163

Hepatitis (Continued) 164

TABLE 79 U S MARKET OF ENZYME INHIBITORS IN HEPATITIS,

THROUGH 2016 ($ MILLIONS) 165

FIGURE 52 U S MARKET OF ENZYME INHIBITORS IN HEPATITIS,

2009-2016 ($ MILLIONS) 165

CANCER 166

Cancer (Continued) 167

TABLE 80 U S MARKET OF ENZYME INHIBITORS IN VARIOUS

CANCER, THROUGH 2016 ($ MILLIONS) 168

FIGURE 53 U S MARKET OF ENZYME INHIBITORS IN VARIOUS

CANCER, 2009-2016 ($ MILLIONS) 168

ERECTILE DYSFUNCTION 168

TABLE 81 U S MARKET OF ENZYME INHIBITORS IN ERECTILE

DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 169

FIGURE 54 U S MARKET OF ENZYME INHIBITORS IN ERECTILE

DYSFUNCTION, 2009-2016 ($ MILLIONS) 170

OTHERS 170

TABLE 82 U S MARKET OF ENZYME INHIBITORS IN OTHER

SECTORS, THROUGH 2016 ($ MILLIONS) 171

FIGURE 55 U S MARKET OF ENZYME INHIBITORS IN OTHER

SECTORS, 2009-2016 ($ MILLIONS) 172

CHAPTER NINE: MARKETS IN EUROPE 173

MARKET ANALYSIS 173

TABLE 83 EUROPEAN MARKET FOR ENZYME INHIBITORS,

THROUGH 2016 ($ MILLIONS) 174

FIGURE 56 EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-

2016 ($ MILLIONS) 175

PROTON PUMP INHIBITORS 175

Market Overview 176

Market Revenue 177

TABLE 84 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS,

THROUGH 2016 ($ MILLIONS) 178

FIGURE 57 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS,

2009-2016 ($ MILLIONS) 178

PROTEASE INHIBITORS 178

Market Overview 179

Market Revenue 180

TABLE 85 EUROPEAN MARKET FOR PROTEASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 180

FIGURE 58 EUROPEAN MARKET FOR PROTEASE INHIBITORS,

2009-2016 ($ MILLIONS) 181

REVERSE TRANSCRIPTASE INHIBITORS 181

Market Overview 181

Market Revenue 182

TABLE 86 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 183

FIGURE 59 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE

INHIBITORS, 2009-2016 ($ MILLIONS) 183

KINASE INHIBITORS 184

Market Overview 184

Market Overview (Continued) 185

Market Revenue 186

TABLE 87 EUROPEAN MARKET FOR KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 186

FIGURE 60 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-

2016 ($ MILLIONS) 186

STATINS 187

Market Overview 187

Market Revenue 188

TABLE 88 EUROPEAN MARKET FOR STATINS, THROUGH 2016 ($

MILLIONS) 189

FIGURE 61 EUROPEAN MARKET FOR STATINS, 2009-2016 ($

MILLIONS) 189

AROMATASE INHIBITORS 189

Market Overview 190

Market Revenue 191

TABLE 89 EUROPEAN MARKET FOR AROMATASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 191

FIGURE 62 EUROPEAN MARKET FOR AROMATASE INHIBITORS,

2009-2016 ($ MILLIONS) 191

PDE5 INHIBITORS 192

Market Overview 192

Market Revenue 192

TABLE 90 EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH

2016 ($ MILLIONS) 193

FIGURE 63 EUROPEAN MARKET FOR PDE5 INHIBITORS,

THROUGH 2016 ($ MILLIONS) 193

NEURAMINIDASE INHIBITORS 194

Market Overview 195

Market Revenue 195

TABLE 91 EUROPEAN MARKET FOR NEURAMINIDASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 195

FIGURE 64 EUROPEAN MARKET FOR NEURAMINIDASE

INHIBITORS, 2009-2016 ($ MILLIONS) 196

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 196

Market Overview 196

Market Revenue 197

TABLE 92 EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH

2016 ($ MILLIONS) 197

FIGURE 65 EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016

($ MILLIONS) 198

MARKET SHARES OF INDUSTRY LEADERS IN EUROPE 198

PROTON PUMP INHIBITORS 198

TABLE 93 EUROPEAN MARKET SHARES OF PROTON PUMP

INHIBITOR MANUFACTURERS, 2010 (%) 199

FIGURE 66 EUROPEAN MARKET SHARES OF PROTON PUMP

INHIBITOR MANUFACTURERS, 2010 (%) 199

PROTEASE INHIBITORS 200

TABLE 94 EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR

MANUFACTURERS, 2010 (%) 200

FIGURE 67 EUROPEAN MARKET SHARES OF PROTEASE

INHIBITORS MANUFACTURERS, 2010 (%) 200

KINASE INHIBITORS 201

TABLE 95 EUROPEAN MARKET SHARES OF KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 201

FIGURE 68 EUROPEAN MARKET SHARES OF KINASE INHIBITORS

MANUFACTURERS, 2010 (%) 202

STATINS 202

TABLE 96 EUROPEAN MARKET SHARES OF STATINS

MANUFACTURERS, 2010 (%) 203

FIGURE 69 EUROPEAN MARKET SHARES OF STATINS

MANUFACTURERS, 2010 (%) 203

AROMATASE INHIBITORS 203

TABLE 97 EUROPEAN MARKET SHARES OF AROMATASE

INHIBITOR MANUFACTURERS, 2010 (%) 204

FIGURE 70 EUROPEAN MARKET SHARES OF AROMATASE

INHIBITOR MANUFACTURERS, 2010 (%) 204

REVERSE TRANSCRIPTASE INHIBITORS 204

TABLE 98 EUROPEAN MARKET SHARES OF REVERSE

TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%) 205

FIGURE 71 EUROPEAN MARKET SHARES OF REVERSE

TRANSCRIPTASE MANUFACTURERS, 2010 (%) 205

PDE5 INHIBITORS 205

TABLE 99 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR

MANUFACTURERS, 2010 (%) 206

FIGURE 72 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR

MANUFACTURERS, 2010 (%) 206

NEURAMINIDASE INHIBITORS 206

TABLE 100 EUROPEAN MARKET SHARES OF NEURAMINIDASE

INHIBITOR MANUFACTURERS, 2010 (%) 207

FIGURE 73 EUROPEAN MARKET SHARES OF NEURAMINIDASE

INHIBITOR MANUFACTURERS, 2010 (%) 207

ACE INHIBITORS 207

TABLE 101 EUROPEAN MARKET SHARES OF ACE INHIBITOR

MANUFACTURERS, 2010 (%) 208

FIGURE 74 EUROPEAN MARKET SHARES OF ACE INHIBITOR

MANUFACTURERS, 2010 (%) 208

MARKET BY APPLICATIONS 208

TABLE 102 EUROPEAN ENZYME INHIBITORS MARKET BY

THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH

2016 ($ MILLIONS) 209

FIGURE 75 EUROPEAN ENZYME INHIBITORS MARKET BY

THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016 ($

MILLIONS) 210

CARDIOVASCULAR (CV) DISEASES 210

Cardiovascular (CV) Diseases 211

TABLE 103 EUROPEAN MARKET OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 212

FIGURE 76 EUROPEAN MARKET OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 212

GASTROINTESTINAL DISORDERS 213

TABLE 104 EUROPEAN MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 214

FIGURE 77 EUROPEAN MARKET OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 214

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 215

TABLE 105 EUROPEAN MARKET OF ENZYME INHIBITORS IN

HIV/AIDS, THROUGH 2016 ($ MILLIONS) 216

FIGURE 78 EUROPEAN MARKET OF ENZYME INHIBITORS IN

HIV/AIDS, 2009-2016 ($ MILLIONS) 216

CANCER 216

Cancer (Continued) 217

TABLE 106 EUROPEAN MARKET OF ENZYME INHIBITORS IN

VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 218

FIGURE 79 EUROPEAN MARKET OF ENZYME INHIBITORS IN

CANCER, 2009-2016 ($ MILLIONS) 219

HEPATITIS 219

TABLE 107 EUROPEAN MARKET OF ENZYME INHIBITORS IN

HEPATITIS, THROUGH 2016 ($ MILLIONS) 220

FIGURE 80 EUROPEAN MARKET OF ENZYME INHIBITORS IN

HEPATITIS, 2009-2016 ($ MILLIONS) 221

ERECTILE DYSFUNCTION 221

TABLE 108 EUROPEAN MARKET OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 222

FIGURE 81 EUROPEAN MARKET OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 222

OTHER DISEASES 222

TABLE 109 EUROPEAN MARKET OF ENZYME INHIBITORS IN

OTHER DISEASES, THROUGH 2016 ($ MILLIONS) 223

FIGURE 82 EUROPEAN MARKET OF ENZYME INHIBITORS IN

OTHER DISEASES, 2009-2016 ($ MILLIONS) 224

CHAPTER TEN: EMERGING MARKETS 225

MARKET ANALYSIS 225

MARKET ANALYSIS (CONTINUED) 226

TABLE 110 EMERGING MARKETS FOR ENZYME INHIBITORS,

THROUGH 2016 ($ MILLIONS) 227

FIGURE 83 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-

2016 ($ MILLIONS) 227

PROTON PUMP INHIBITORS 228

Market Overview 228

Market Revenue 229

TABLE 111 EMERGING MARKETS FOR PROTON PUMP

INHIBITORS, THROUGH 2016 ($ MILLIONS) 229

FIGURE 84 EMERGING MARKETS FOR PROTON PUMP

INHIBITORS, 2009-2016 ($ MILLIONS) 230

PROTEASE INHIBITORS 230

Market Overview 231

Market Revenue 231

TABLE 112 EMERGING MARKETS FOR PROTEASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 232

FIGURE 85 EMERGING MARKETS FOR PROTEASE INHIBITORS,

2009-2016 ($ MILLIONS) 232

REVERSE TRANSCRIPTASE INHIBITORS 232

Market Overview 233

Market Revenue 234

TABLE 113 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 235

FIGURE 86 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE

INHIBITORS, 2009-2016 ($ MILLIONS) 235

KINASE INHIBITORS 235

Market Overview 236

Market Revenue 237

TABLE 114 EMERGING MARKETS FOR KINASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 237

FIGURE 87 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-

2016 ($ MILLIONS) 238

STATINS 238

Market Overview 238

Market Overview (Continued) 239

Market Revenue 240

TABLE 115 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($

MILLIONS) 240

FIGURE 88 EMERGING MARKETS FOR STATINS, 2009-2016 ($

MILLIONS) 241

AROMATASE INHIBITORS 241

Market Overview 241

Market Revenue 242

TABLE 116 EMERGING MARKETS FOR AROMATASE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 242

FIGURE 89 EMERGING MARKETS FOR AROMATASE INHIBITORS,

2009-2016 ($ MILLIONS) 242

PDE5 INHIBITORS 243

Market Overview 243

Market Revenue 243

TABLE 117 EMERGING MARKETS FOR PDE5 INHIBITORS,

THROUGH 2016 ($ MILLIONS) 244

FIGURE 90 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-

2016 ($ MILLIONS) 244

NEURAMINIDASE INHIBITORS 244

Market Overview 245

Market Revenue 245

TABLE 118 EMERGING MARKETS FOR NEURAMINIDASE

INHIBITORS, THROUGH 2016 ($ MILLIONS) 246

FIGURE 91 EMERGING MARKETS FOR NEURAMINIDASE

INHIBITORS, 2009-2016 ($ MILLIONS) 246

ACE INHIBITORS 246

Market Overview 247

Market Revenue 247

TABLE 119 EMERGING MARKETS FOR ACE INHIBITORS,

THROUGH 2016 ($ MILLIONS) 248

FIGURE 92 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016

($ MILLIONS) 248

MARKET SHARES OF INDUSTRY LEADERS IN EMERGING

MARKETS 248

PROTON PUMP INHIBITORS 248

TABLE 120 EMERGING MARKET SHARES OF PROTON PUMP

INHIBITOR MANUFACTURERS, 2010 (%) 249

FIGURE 93 EMERGING MARKET SHARES OF PROTON PUMP

INHIBITOR MANUFACTURERS, 2010 (%) 249

PROTEASE INHIBITORS 249

TABLE 121 EMERGING MARKET SHARES OF PROTEASE

INHIBITOR MANUFACTURERS, 2010 (%) 250

FIGURE 94 EMERGING MARKETS SHARES OF PROTEASE

INHIBITORS MANUFACTURERS, 2010 (%) 250

KINASE INHIBITORS 251

TABLE 122 EMERGING MARKET SHARES OF KINASE INHIBITOR

MANUFACTURERS, 2010 (%) 251

FIGURE 95 EMERGING MARKET SHARES OF KINASE INHIBITORS

MANUACTURERS, 2010 (%) 252

STATINS 252

TABLE 123 EMERGING MARKET SHARES OF STATINS

MANUFACTURERS, 2010 (%) 252

FIGURE 96 EMERGING MARKETS SHARES OF STATINS

MANUFACTURERS, 2010 (%) 253

AROMATASE INHIBITORS 253

TABLE 124 EMERGING MARKET SHARES OF AROMATASE

INHIBITOR, 2010 (%) 253

FIGURE 97 EMERGING MARKET SHARES OF AROMATASE

INHIBITOR MANUFACTURERS, 2010 (%) 254

REVERSE TRANSCRIPTASE INHIBITORS 254

TABLE 125 EMERGING MARKET SHARES OF REVERSE

TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%) 254

FIGURE 98 EMERGING MARKET SHARES OF REVERSE

TRANSCRIPTASE MANUFACTURERS, 2010 (%) 255

PDE5 INHIBITORS 255

TABLE 126 EMERGING MARKET SHARES OF PDE5 INHIBITOR

MANUFACTURERS, 2010 (%) 255

FIGURE 99 EMERGING MARKET SHARES OF PED5

MANUFACTURERS, 2010 (%) 256

NEURAMINIDASE INHIBITORS 256

TABLE 127 EMERGING MARKET SHARES OF NEURAMINIDASE

INHIBITOR MANUFACTURERS, 2010 (%) 256

FIGURE 100 EMERGING MARKET SHARES OF NEURAMINIDASE

MANUFACTURERS, 2010 (%) 257

ACE INHIBITORS 257

TABLE 128 EMERGING MARKET SHARES OF ACE INHIBITOR

MANUFACTURERS, 2010 (%) 257

FIGURE 101 EMERGING MARKET SHARES OF ACE INHIBITOR

MANUFACTURERS, 2010 (%) 258

MARKET BY APPLICATIONS 258

TABLE 129 EMERGING MARKETS IN ENZYME INHIBITORS BY

THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH

2016 ($ MILLIONS) 259

FIGURE 102 EMERGING MARKETS IN ENZYME INHIBITORS BY

THERAPEUTIC CATEGORIES/DISEASE SECTORS ($ MILLIONS) 259

CARDIOVASCULAR (CV) DISEASE 260

Cardiovascular (CV) Disease (Continued) 261

TABLE 130 EMERGING MARKETS OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASES, THROUGH 2016 ($ MILLIONS) 262

FIGURE 103 EMERGING MARKETS OF ENZYME INHIBITORS IN

CARDIOVASCULAR DISEASES, 2009-2016 ($ MILLIONS) 262

GASTROINTESTINAL DISORDERS 263

TABLE 131 EMERGING MARKETS OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASES, THROUGH 2016 ($ MILLIONS) 263

FIGURE 104 EMERGING MARKETS OF ENZYME INHIBITORS IN

GASTROINTESTINAL DISEASES, 2009-2016 ($ MILLIONS) 264

ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 264

TABLE 132 EMERGING MARKETS OF ENZYME INHIBITORS IN

HIV/AIDS, THROUGH 2016 ($ MILLIONS) 265

FIGURE 105 EMERGING MARKETS OF ENZYME INHIBITORS IN

HIV/AIDS, 2009-2016 ($ MILLIONS) 266

HEPATITIS 266

TABLE 133 EMERGING MARKETS OF ENZYME INHIBITORS IN

HEPATITIS, THROUGH 2016 ($ MILLIONS) 267

FIGURE 106 EMERGING MARKETS OF ENZYME INHIBITORS IN

HEPATITIS, 2009-2016 ($ MILLIONS) 268

CANCER 268

TABLE 134 EMERGING MARKETS OF ENZYME INHIBITORS IN

VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 269

FIGURE 107 EMERGING MARKETS OF ENZYME INHIBITORS IN

VARIOUS CANCERS, 2009-2016 ($ MILLIONS) 270

ERECTILE DYSFUNCTION (ED) 270

TABLE 135 EMERGING MARKETS OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 271

FIGURE 108 EMERGING MARKETS OF ENZYME INHIBITORS IN

ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 271

OTHER DISEASES 271

TABLE 136 EMERGING MARKETS OF ENZYME INHIBITORS IN

OTHER DISEASES, THROUGH 2016 ($ MILLIONS) 272

FIGURE 109 EMERGING MARKETS OF ENZYME INHIBITORS IN

OTHER DISEASES, 2009-2016 ($ MILLIONS) 273

CHAPTER ELEVEN: PATENT ANALYSIS 274

PATENTS BY YEAR 274

TABLE 137 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008–

2012 275

FIGURE 110 NUMBER OF PATENTS BY YEAR, 2008–2012 275

FIGURE 111 NUMBER OF PATENTS BY YEAR, 2008–2012 (%) 276

PATENTS BY TYPE 276

TABLE 138 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–

2012 277

FIGURE 112 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–

2012 277

PATENTS BY COMPANY 278

TABLE 139 NUMBER OF U S PATENTS BY COMPANY FOR ENZYME

INHIBITORS, 2008–2012 278

TABLE 139 (CONTINUED) 279

PATENTS BY COUNTRY 280

TABLE 140 TOTAL NUMBER OF U S PATENTS BY COUNTRY FOR

ENZYME INHIBITORS, 2008–2012 280

FIGURE 113 TOTAL NUMBER OF U S PATENTS BY COUNTRY FOR

ENZYME INHIBITORS, 2008–2012 281

TABLE 141 PATENT SHARES BY COUNTRY FOR INDUSTRIAL

ENZYMES, 2008–2012 (%) 281

FIGURE 114 PATENT SHARES BY COUNTRY FOR ENZYME

INHIBITORS, 2008–2012 (%) 282

PATENTS BY ASSIGNEE 282

TABLE 142 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008–

2012 282

FIGURE 115 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES,

2008–2012 (%) 283

CHAPTER TWELVE: CURRENT SITUATION 284

MARKET CONDITIONS 284

UNITED STATES 284

EUROPE 284

EMERGING MARKETS 285

TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 285

COMPETITION 285

PATENT EXPIRATIONS 285

UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT

CLIFF 286

PATENT CHALLENGES / LEGAL PROCEEDINGS 286

NEW INDICATIONS APPROVED 286

NEW DRUG APPROVALS 287

RX- TO- OTC SWITCH 287

INCREASING NUMBER OF BABY BOOMERS 288

MERGERS AND ACQUISITIONS AND ALLIANCES 288

DIRECT-TO-CONSUMER ADVERTISING 289

CHAPTER THIRTEEN: COMPANY PROFILES

To order this report: Drug and Medication Industry: Global Markets for Enzyme Inhibitors 

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626



'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
2. Genitourinary Drugs: Technologies and Global Markets
3. Marken Announces Global Advisory Board
4. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
5. Asthma and COPD Drug Market Expected to Reach USD 26,965.5 Million Globally in 2017: Transparency Market Research
6. MMRGlobal and Fujitsu Offer Low-Cost System to Digitize Medical Records
7. ResearchMoz: Global Power Wheelchairs Market Will Reach $3.9 Billion by 2018 - Market Research Report
8. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Honored Dr. Thomas Fogarty with the 2012 Lifetime Achievement Award
10. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
11. Oriel STAT A MATRIX Welcomes New Global Practice Head for Medical Devices and Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... world,s largest abstract and citation database of peer-reviewed literature, providing the ... 5,000 publishers. The new set of metrics will improve decisions on ... adjust a journal,s editorial strategy. ... , CiteScore metrics comprise ...
(Date:12/8/2016)... December 8, 2016 According to the ... Pens Market is expected to be worth US$9.7 bn ... in 2015. Between the forecast years of 2016 and 2024, ... of 7.9%. The leading players operating in the global diabetes ... Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market ...
Breaking Medicine Technology:
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental health ... health systems reform legislation in more than fifty years. We applaud the bipartisan ... our elected officials to improving mental health services and supports in our nation. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader that ... a new partnership with Splashtop Inc. This remote control for Android extends Wavelink’s ... businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility management ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... acquired Presence Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 ... other considerations. Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, ...
Breaking Medicine News(10 mins):